GlassScriptPhysician profile
Elizabeth Kaback
NPI 1689641169
$3,040.69
in general payments reported to CMS, 2019-2025
27 companies · $802 in 2025
The $802 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $68.11 · 2021: $167 · 2022: $385 · 2023: $598 · 2024: $528 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,927.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $423.16 | 2019-2025 | |
| Medtronic, INC. | $264.58 | 2022-2025 | Linq II |
| Pfizer INC. | $230.25 | 2023-2025 | |
| Exact Sciences Corporation | $217.30 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $200.07 | 2019-2025 | Watchman Flx |
| Biotronik INC. | $192.65 | 2019-2020 | |
| Novo Nordisk INC | $160.52 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.46 | 2021-2023 | Jardiance |
| Esperion Therapeutics, INC. | $141.87 | 2021-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.71 | 2022-2025 | Xifaxan |
| Amarin Pharma, INC. | $118.93 | 2019 | |
| Heartflow, INC. | $102.19 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.53 | 2025 | Lifevest |
| Amgen INC. | $87.89 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $84.95 | 2021-2023 | Farxiga |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $81.96 | 2022-2025 | Mounjaro, Zepbound |
| Itamar Medical INC | $51.63 | 2022-2025 | Watchpatone |
| Kiniksa Pharmaceuticals, LTD. | $49.11 | 2022 | |
| Baxter Healthcare | $43.77 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $42.03 | 2019-2024 | Evkeeza |
| Medtronic Vascular, INC. | $36.02 | 2019 | |
| Irhythm Technologies, INC. | $26.48 | 2022 | |
| Cleerly, INC. | $25.33 | 2025 | Cleerly Labs, Cleerly Ischemia |
| E.R. Squibb & Sons, L.L.C. | $20.49 | 2022 | |
| Daiichi Sankyo INC. | $20.08 | 2022 | |
| Gilead Sciences, INC. | $19.34 | 2019 | |
| Recordati_rare_diseases_inc. | $16.39 | 2024 | Signifor Lar, Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Kaback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.